ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
HER2 Positive Metastatic Breast Cancer
Interventions
DRUG

ARX788

The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269

Trial Locations (64)

3135

WITHDRAWN

Research Site, Ringwood East

3168

WITHDRAWN

Research Site, Clayton

3199

COMPLETED

Research Site, Frankston

3220

COMPLETED

Research Site, Geelong

4101

WITHDRAWN

Research Site, South Brisbane

4102

WITHDRAWN

Research Site, Woolloongabba

6009

COMPLETED

Research Site, Nedlands

10016

WITHDRAWN

Research Site, New York

10028

RECRUITING

Research Site, New York

10065

WITHDRAWN

Research Site, New York

10408

WITHDRAWN

Research Site, Goyang-si

10469

RECRUITING

Research Site, The Bronx

11042

RECRUITING

Research Site, New Hyde Park

11967

RECRUITING

Research Site, Shirley

13620

COMPLETED

Research Site, Seongnam-si

16499

WITHDRAWN

Research Site, Suwon

17019

WITHDRAWN

Research Site, La Rochelle

19104

RECRUITING

Research Site, Philadelphia

19713

WITHDRAWN

Research Site, Newark

20904

RECRUITING

Research Site, Silver Spring

21093

WITHDRAWN

Research Site, Lutherville

23502

RECRUITING

Research Site, Norfolk

30322

RECRUITING

Research Site, Atlanta

30607

RECRUITING

Research Site, Athens

31059

WITHDRAWN

Research Site, Toulouse

32806

WITHDRAWN

Research Site, Orlando

33028

WITHDRAWN

Research Site, Hollywood

37203

RECRUITING

Research Site, Nashville

37404

WITHDRAWN

Research Site, Chattanooga

40207

RECRUITING

Research Site, Louisville

42601

COMPLETED

Research Site, Daegu

60611

RECRUITING

Research Site, Chicago

63110

WITHDRAWN

Research Site, St Louis

65613

RECRUITING

Research Site, Bolivar

68130

RECRUITING

Research Site, Omaha

70809

WITHDRAWN

Research Site, Baton Rouge

72000

WITHDRAWN

Research Site, Le Mans

75246

RECRUITING

Research Site, Dallas

75702

WITHDRAWN

Research Site, Tyler

75705

WITHDRAWN

Research Site, Plano

77030

RECRUITING

Research Site, Houston

78731

WITHDRAWN

Research Site, Austin

84918

WITHDRAWN

Research Site, Avignon

87109

WITHDRAWN

Research Site, Albuquerque

89128

COMPLETED

Research Site, Las Vegas

90025

WITHDRAWN

Research Site, West Los Angeles

90033

RECRUITING

Research Site, Los Angeles

90095

WITHDRAWN

Research Site, Los Angeles

90505

WITHDRAWN

Research Site, Torrance

90602

RECRUITING

Research Site, Whittier

92663

RECRUITING

Research Site, Newport Beach

93105

WITHDRAWN

Research Site, Santa Barbara

94158

RECRUITING

Research Site, San Francisco

97213

COMPLETED

Research Site, Portland

97223

RECRUITING

Research Site, Tigard

98405

RECRUITING

Research Site, Tacoma

02215

RECRUITING

Research Site, Boston

08103

RECRUITING

Research Site, Camden

Unknown

WITHDRAWN

Research Site, Melbourne

06189

WITHDRAWN

Research Site, Nice

02841

COMPLETED

Research Site, Seoul

03722

COMPLETED

Research Site, Seoul

05505

COMPLETED

Research Site, Seoul

06351

WITHDRAWN

Research Site, Seoul

All Listed Sponsors
lead

Ambrx, Inc.

INDUSTRY

NCT04829604 - ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | Biotech Hunter | Biotech Hunter